SEC Company Response from CTI BIOPHARMA CORP (CIK 0000891293) — Aug 23, 2022
CTI BIOPHARMA CORP (CIK 0000891293)
Date: Aug. 23, 2022 · CIK: 0000891293 · Accession: 0001193125-22-227502
AI Filing Summary & Sentiment
File numbers found in text: 333-266926
Letter
Re: CTI BioPharma Corp.
August 23, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3 (File No. 333-266926)
To Whom it May Concern:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), CTI BioPharma Corp. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 25, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel request by telephone that such Registration Statement be declared effective at some other time.
Once the Registration Statement is effective, please confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden C. Berns at (917) 302-4510 or emailing bberns@gibsondunn.com.
Sincerely,
CTI BioPharma Corp.
Show Raw Text
CORRESP 1 filename1.htm CORRESP August 23, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CTI BioPharma Corp. Registration Statement on Form S-3 (File No. 333-266926) To Whom it May Concern: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), CTI BioPharma Corp. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 25, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel request by telephone that such Registration Statement be declared effective at some other time. Once the Registration Statement is effective, please confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden C. Berns at (917) 302-4510 or emailing bberns@gibsondunn.com. Sincerely, CTI BioPharma Corp. /s/ David Kirske David Kirske Chief Financial Officer cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP